Significant Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series

References (18)

1. Witkiewitz K, Litten RZ, Leggio L. Advances in the science and treatment of alcohol use disorder. Sci Adv. 2019;5(9):eaax4043. PubMed CrossRef
2. Han B, Jones CM, Einstein EB, et al. Use of medications for alcohol use disorder in the US: results from the 2019 National Survey on Drug Use and Health. JAMA Psychiatry. 2021;78(8):922–924. PubMed CrossRef
3. Jerlhag E. The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies. Front Pharmacol. 2023;14:1063033. PubMed CrossRef
4. Chuong V, Farokhnia M, Khom S, et al. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight. 2023;8(12):e170671. PubMed CrossRef
5. Aranäs C, Edvardsson CE, Shevchouk OT, et al. Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. EBioMedicine. 2023;93:104642. PubMed CrossRef
6. Klausen MK, Jensen ME, Møller M, et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. 2022;7(19):e159863. PubMed CrossRef
7. Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117–124. PubMed CrossRef
8. Rubino DM, Greenway FL, Khalid U, et al; STEP 8 Investigators. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022;327(2):138–150. PubMed CrossRef
9. Thomsen M, Holst JJ, Molander A, et al. Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys. Psychopharmacology (Berl). 2019;236(2):603–611. PubMed CrossRef
10. Wium-Andersen IK, Wium-Andersen MK, Fink-Jensen A, et al. Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events: a nationwide register-based cohort and self-controlled case series study. Basic Clin Pharmacol Toxicol. 2022;131(5):372–379. PubMed CrossRef
11. Azam H, Shahrestani S, Phan K. Alcohol use disorders before and after bariatric surgery: a systematic review and meta-analysis. Ann Transl Med. 2018;6(8):148. PubMed CrossRef
12. Saunders JB, Aasland OG, Babor TF, et al. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on early detection of persons with harmful alcohol consumption–II. Addiction. 1993;88(6):791–804. PubMed CrossRef
13. Conigrave KM, Hall WD, Saunders JB. The AUDIT questionnaire: choosing a cut-off score. Alcohol Use Disorder Identification Test. Addiction. 1995;90(10):1349–1356. PubMed CrossRef
14. Babor TF, Higgins-Biddle J, Saunders JB, et al. World Health Organization. AUDIT-The Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Heath Care. Second Edition. 2001:1–40.
15. Shinn AK, Greenfield SF. Topiramate in the treatment of substance-related disorders: a critical review of the literature. J Clin Psychiatry. 2010;71(5):634–648. PubMed CrossRef
16. Reus VI, Fochtmann LJ, Bukstein O, et al. The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. Am J Psychiatry. 2018;175(1):86–90. PubMed CrossRef
17. Connor JP, Haber PS, Hall WD. Alcohol use disorders. Lancet. 2016;387(10022):988–998. PubMed CrossRef
18. Marty VN, Farokhnia M, Munier JJ, et al. Long-acting glucagon-like peptide-1 receptor agonists suppress voluntary alcohol intake in male wistar rats. Front Neurosci. 2020;14:599646. PubMed CrossRef